Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navicixizumab plus paclitaxel in platinum-resistant ovarian cancer
NCT03030287Phase 1Completed
- Sponsor
- OncoMed Pharmaceuticals
- Start
- Dec 2016
- Primary completion
- Apr 2020
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of navicixizumab in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by OncoMed Pharmaceuticals. Primary endpoint: Incidence of dose limiting toxicities at 28 days. Started Dec 2016; status: completed.
02
Drugs
navicixizumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT03030287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03030287.